Pliant Therapeutics Inc. (PLRX) News
Filter PLRX News Items
PLRX News Results
|Loading, please wait...|
PLRX News Highlights
- PLRX's 30 day story count now stands at 4.
- Over the past 7 days, the trend for PLRX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about PLRX are NOV.
Latest PLRX News From Around the Web
Below are the latest news stories about PLIANT THERAPEUTICS INC that investors may wish to consider to help them evaluate PLRX as an investment opportunity.
SOUTH SAN FRANCISCO, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced participation in the following November investor conferences: Evercore 4th Annual ISI HealthCONx Virtual Conference Members of Pliant’s senior management team will participate in meetings with the investment community on Tuesday, November 29, 2022Piper
Needham analyst Joseph Stringer reiterated a Buy rating on Pliant Therapeutics (PLRX - Research Report) today and set a price target of $40.00. The company's shares closed yesterday at $21.30.Stringer covers the Healthcare sector, focusing on stocks such as Vaxcyte, Avidity Biosciences, and Cidara Therapeutics. According to TipRanks, Stringer has an average return of -0.4% and a 40.61% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Pliant Therapeutics with a $45.25 average price target.
Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of 12.16% and 34.43%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported third quarter 2022 financial results. “Our strong third quarter progress was highlighted by positive data from our lead candidate PLN-74809 in IPF, the further strengthening of our financial position through a successful
Here is how Assertio (ASRT) and Pliant Therapeutics, Inc. (PLRX) have performed compared to their sector so far this year.
Aveo Pharmaceuticals (AVEO) is set to be acquired by LG Chem for an aggregate amount of $566 billion. The deal is expected to close by early 2023. Stock up.
Pliant Therapeutics to Participate in the RBC Biotech Expert Insights Series: Pulmonary/Lung Disease Mini-Symposium
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, and Greg Cosgrove, M.D., FCCP, Vice President, Clinical Development, will present a corporate overview at the Pulmonary/Lung Disease Mini-Symposium, a part of RBC’s Biotech Expert
Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) institutional investors lost 12% last week but have benefitted from longer-term gains
Every investor in Pliant Therapeutics, Inc. ( NASDAQ:PLRX ) should be aware of the most powerful shareholder groups...
In this article, we will look at Harvard University’s latest stock portfolio and list its 10 best biotech stock picks. If you want to explore more biotech stocks that make up the top holdings of Harvard Management, you can also take a look at Harvard University’s Latest Portfolio: 5 Best Biotech Stock Picks. Harvard Management […]
SOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced the appointment of Dr. Katharine Knobil to its Board of Directors, effective immediately. “I would like to extend a warm welcome to Kate whose global clinical development and strategic leadership experience, including her training as a pulmonologist,